Format

Send to

Choose Destination
See comment in PubMed Commons below
Orphanet J Rare Dis. 2014 Apr 10;9:48. doi: 10.1186/1750-1172-9-48.

Concerns about unapproved meningococcal vaccination for eculizumab therapy in Japan.

Author information

1
Department of Internal Medicine, Navitas Clinic, 3-1-1, Shibasaki-cho, 190-0023 Tachikawa, Tokyo, Japan. tetanimot@yahoo.co.jp.

Abstract

An orphan medicinal product, eculizumab is approved in Japan and globally for treating paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome. Eculizumab therapy can cause late complement pathway deficiencies that predispose patients to meningococcal infections. Although meningococcal vaccinations are typically considered mandatory for eculizumab therapy, no approved vaccine is available in Japan as of March, 2014. Advertising unapproved, privately imported pharmaceuticals is prohibited under Japanese pharmaceutical law; detailed information concerning the unapproved meningococcal vaccines is therefore not widely available. The situation jeopardizes the safety of patients receiving eculizumab therapy, and Japanese clinicians are advised caution when prescribing this therapy.

PMID:
24716834
PMCID:
PMC3990028
DOI:
10.1186/1750-1172-9-48
[Indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for BioMed Central Icon for PubMed Central
    Loading ...
    Support Center